Drugs / cPCV7
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03550313 | Jun 2018 → Nov 2020 | pneumococcal infection | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT03313050 | Oct 2017 → May 2019 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cPCV7 | “A complementary 7-valent PCV (cPCV7) including polysaccharide conjugates from 7 non-13-valent (PCV13) serotypes was developed to potentially complement PCV13-mediated...” PMID 37927075 ↗ Nov 20231“This phase 1/2, randomized, active-controlled, observer-blinded study evaluated cPCV7 safety and immunogenicity in healthy adults 50-85 years of age.” PMID 33661716 ↗ Mar 2021 |
| Known as | complementary 7-valent PCV | “The complementary 7-valent PCV (cPCV7) contains seven non-PCV13 serotypes (8, 10A, 11A, 12F, 15B, 22F, 33F) and can expand coverage by supplementing direct or indirect...” PMID 33661716 ↗ Mar 2021 |
| Modality | Vaccine | “A complementary 7-valent PCV (cPCV7) including polysaccharide conjugates from 7 non-13-valent (PCV13) serotypes was developed to potentially complement PCV13-mediated...” PMID 37927075 ↗ Nov 2023 |